8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 4, 2026·SEC
Material company update
Jan 20, 2026·SEC
enVVeno Medical Corporation(NVNO)Earnings, Financials & Key Ratios
NVNO•NASDAQ
$10.84
Price updated Jun 27, 2026
AboutenVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.Show more
- Revenue$0
- EBITDA-$20M+12.4%
- Net Income-$19M+10.8%
- EPS (Diluted)-33.06+97.9%
- ROE-56.21%-13.8%
NVNO Price & Volume
enVVeno Medical Corporation (NVNO) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Clinical Trial Outcome
"enVVeno Medical remains in a pre-commercial phase, with its valuation entirely dependent on the successful clinical progression of the VenoValve and enVVe systems. The company faces significant financial headwinds, characterized by persistent net losses and a lack of revenue, which necessitates ongoing reliance on dilutive equity financing. Investors should monitor the company's ability to extend its limited cash runway, as the current burn rate threatens the continuity of its pivotal clinical trials."
Verdict Logic
the company's cash position of $2.6 million as of 2026Q1 appears insufficient to sustain ongoing clinical operations without immediate, highly dilutive external financing.
NVNO Growth Metrics
enVVeno Medical Corporation (NVNO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM11.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.13%
Return on Capital
10 Years-161.62%
5 Years-55.02%
3 Years-56.7%
Last Year-59.46%
NVNO Recent Earnings
enVVeno Medical Corporation (NVNO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$5.89+29.9%
$8.40
Rev
—
$500,000
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$10.53-7.4%
$9.80
Rev
—
$3M
Q4 2025
Oct 31, 2025Metric
Actual
Est
EPS
$8.07+23.1%
$10.50
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.33-17.9%
$0.28
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $5.89vs $8.40+29.9% | —vs $500,000 |
| Q2 2026 | Mar 26, 2026 | $10.53vs $9.80-7.4% | —vs $3M |
| Q4 2025 | Oct 31, 2025 | $8.07vs $10.50+23.1% | — |
| Q3 2025 | Jul 31, 2025 | $0.33vs $0.28-17.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for enVVeno Medical Corporation (NVNO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.84 | $7.09M | -0.33 | — | — | -56.21% | — | |
| $1.28 | $6.85M | -0.29 | 40.04% | -997.46% | — | — | |
| $0.74 | $33.17M | -0.89 | 15.84% | -49.3% | -1344.47% | — | |
| $15.43 | $1.76B | -12.65 | 8.28% | -25.66% | -50.82% | — | |
| $13.40 | $553.67M | -16.14 | -3.76% | -10% | -17.65% | — | |
| $41.46 | $343.29M | 48.21 | 16.97% | 14.08% | 22.14% | — |
Compare NVNO vs Peers
enVVeno Medical Corporation (NVNO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVNO SEC Filings & Documents
enVVeno Medical Corporation (NVNO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NVNO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVNO Frequently Asked Questions
enVVeno Medical Corporation (NVNO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NVNO profitable?
enVVeno Medical Corporation (NVNO) reported a net loss of $18.8M for fiscal year 2025.
Dividend & Returns
What is NVNO's return on equity?
enVVeno Medical Corporation (NVNO) has a return on equity (ROE) of -56.2%. Negative ROE indicates the company is unprofitable.
What is enVVeno Medical Corporation's free cash flow?
enVVeno Medical Corporation (NVNO) had negative free cash flow of $14.8M in fiscal year 2025, likely due to heavy capital investments.